Study of sacituzumab tirumotecan for advanced anal or rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new medication, sacituzumab tirumotecan, for people with anal or rectal cancer that has spread or cannot be removed and has not responded to previous treatments. The drug is designed to target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anal or rectal squamous cell carcinoma that has spread to other parts of the body or cannot be removed with surgery.
- You have had at least one but no more than three prior treatments for advanced disease, including chemotherapy and immunotherapy.
- You are at least 18 years old.
- You are able to perform daily activities with minimal help (ECOG 0 or 1).
- You have a tissue sample (biopsy) available for testing.
- You agree to use effective birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called sacituzumab tirumotecan for thymic carcinoma that has spread or come back after prior treatment. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a new drug called sacituzumab tirumotecan for penile cancer that has spread or cannot be cured with surgery or radiation. It is for people whose cancer got worse after standard chemotherapy. The drug is given as an infusion and may help shrink tumors or slow the cancer's growth.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.